MK3475-054
Laufzeit: 01.01.2016 - 31.12.2017
imported
Kurzfassung
PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group
